ANGOSTURA
12.2.2020 18:47:05 CET | Business Wire | Press release
The House of Angostura® has announced that world-renowned Trinidadian-born DJ, music producer and entrepreneur Christopher “Jillionaire” Leacock will add some star quality to the judging panel, and the celebration, at this year’s Angostura Global Cocktail Challenge. This biannual event, celebrates its 10th anniversary in 2020 and brings together bartenders worldwide for the chance to become the global champion. The Angostura® Global Cocktail Challenge Finals takes place on February 22 in Trinidad & Tobago, ahead of the greatest show on earth, Trinidad & Tobago Carnival.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200212005699/en/
Peter Sandström, CEO of Angostura® , comments: “The Angostura® Global Cocktail Challenge is the 10th anniversary of the competition and we wanted to do something special to mark the occasion. Partnering with Jillionaire made so much sense as his roots are inherently connected to the House of Angostura® . He has a strong understanding of Angostura’s place at the heart of Trinidad & Tobago culture, enormous passion for locally inspired music and drinks and his global following helps elevate the competition to showcase the extraordinary talents of our competitors to an international audience.”
The nine finalists of the Angostura® Global Cocktail Competition 2020 are: Shana Rajahram (Trinidad & Tobago), Marv Cunningham (The Bahamas), Chad Lawrence (Canada), Gustavo Costa (Brazil), Mike Jordhoy (France), Rohan Massie (Australia), Simon Dacey (United Kingdom), Vasile Dorofeev (Dubai) and Agung Satria (Vietnam).
Jillionaire, best known for his contributions to Major Lazer, an American electronic music group, brings a keen interest and understanding of the bar industry as part-owner of Clyde’s, a Trinidadian cocktail bar in Brooklyn, New York. He is well prepared to see the nine finalists compete, as they aim to wow the judges with cocktail prowess.
Jillionaire shares why he’s proud to join the Angostura® Global Cocktail Challenge judging panel: “I am a proud supporter of Trinidadian culture and have a personal interest in cocktail culture and one of our island’s biggest exporter - Angostura® . Angostura’s historic bitters are known the world over. I’m keen to shine a light on our celebrated rum and amaro which capture the flavours of Trinidad & Tobago. Whoever goes on to win the competition, will not only be representing Angostura® , they’ll be representing our island on the world stage, something I take seriously.”
Angostura Global Cocktail Competition Master of Ceremonies and Judging Panel
Jillionaire will join head judge and James Beard Award-winning beverage professional, Maxwell Britten. Other judges include Eryn Reece, Bar Director at The Wooly Public, Joe Schofield, co-owner of Schofield’s Bar, Angostura® Chief Brand Educator, Raymond Edwards, and the reigning Angostura® Global Cocktail Challenge Champion, Raymond Letoa. Hospitality industry veteran Ms Franky Marshall will serve as Master of Ceremonies. After the competition, Jillionaire will lead the after-party celebrations, performing a curated DJ set.
The winning bartender will receive the coveted title of “Angostura® Global Cocktail Challenge (AGCC) Champion,” a cash prize of US$10,000 and a two-year contract as the Angostura® Global Brand Ambassador for ANGOSTURA® aromatic bitters, ANGOSTURA® orange bitters, Angostura® Rums and Amaro di ANGOSTURA® , as well as the opportunity to revisit Angostura’s home in Trinidad & Tobago to serve as a judge at the next edition of the competition.
For more information about the competition, visit www.AngosturaGlobalCocktailChallenge.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200212005699/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom